Page last updated: 2024-12-10

1-hydroxy-4-oxahomoadamantan-5-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-hydroxy-4-oxahomoadamantan-5-one is a **synthetic organic compound** with the following key features:

* **Structure:** It contains a **fused bicyclic ring system** resembling adamantane (a diamond-shaped molecule) with an oxygen atom replacing a carbon atom in the ring. It also features a hydroxyl group (OH) and a ketone group (C=O).
* **Synthesis:** This compound is not found naturally and needs to be **synthesized in the laboratory**. Its synthesis is typically based on multi-step reactions involving organic chemistry techniques.

**Why is it important for research?**

The importance of 1-hydroxy-4-oxahomoadamantan-5-one lies in its potential applications in various research areas, including:

* **Medicinal chemistry:** The unique structural features of this compound make it a potential candidate for **drug development**. Its rigid structure could be used to develop molecules that bind specifically to biological targets, potentially leading to new therapies for diseases.
* **Material science:** Its rigid structure and potential for functionalization make it a potential building block for **advanced materials**. For example, it could be incorporated into polymers to impart specific properties like strength, rigidity, or thermal stability.
* **Organic synthesis:** This compound can serve as a versatile **starting material for the synthesis of other complex molecules**. Its unique structural features could be exploited to create new synthetic pathways.

**Current Research:**

Current research on 1-hydroxy-4-oxahomoadamantan-5-one is mainly focused on:

* **Developing efficient synthetic routes** for its production.
* **Exploring its pharmacological activity** to determine its potential as a drug candidate.
* **Investigating its applications in materials science** for the development of new materials with desired properties.

**Overall, 1-hydroxy-4-oxahomoadamantan-5-one is a promising compound with potential applications in various fields. Continued research on this molecule will likely uncover new insights and applications in the future.**

Cross-References

ID SourceID
PubMed CID3239817
CHEMBL ID1742315
CHEBI ID19051
SCHEMBL ID5191526

Synonyms (13)

Synonym
1-hydroxy-4-oxatricyclo[4.3.1.1(3,8)]undecan-5-one
CHEBI:19051 ,
1-hydroxy-4-oxahomoadamantan-5-one
1-hydroxy-4-oxatricyclo[4.3.1.1~3,8~]undecan-5-one
MLS000043044
smr000019471
EU-0013447
HMS2388C17
SCHEMBL5191526
1-hydroxy-4-oxatricyclo[4.3.1.13,8]undecan-5-one
IYOCRSOAYQUGEF-UHFFFAOYSA-N
CHEMBL1742315
Q27109105
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
epsilon-lactoneAny lactone with a seven-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.00000.003245.467312,589.2998AID2517
TDP1 proteinHomo sapiens (human)Potency4.10950.000811.382244.6684AID686978
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency9.46620.168316.404067.0158AID720504
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]